| REVIEW ARTICLE |
|
| Year : 2011 | Volume
: 1
| Issue : 2 | Page : 116-125 |
|
|
Effect of metformin combined therapy in patients with polycystic ovary syndrome
Dhanalakshmi Ganesan1, Sumathi Palaniswamy2, Pasupathy Palanisamy3, Babu Shankar Ponnusha3, Ambika Athimoolam3
1 Department of Biochemistry & Biotechnology, Bharathiyar University, Coimbatore, India
2 Department of Biochemistry, Government Arts and Science College for women, Krishnagiri, India
3 Clinical Biochemistry, K. G. Hospital and Post graduate Medical Institute, Coimbatore, Tamil Nadu, India
Correspondence Address:
Dhanalakshmi Ganesan
Research scholar, Bharathiyar university, Coimbatore, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2231-0738.84201
|
|
|
Polycystic ovary syndrome (PCOS) is a common and heterogeneous disorder of women of reproductive age, characterized by hyperandrogenism and chronic anovulation. Metformin may lower the androgen level in follicular fluid, affecting local levels of IGF (Insulin like growth factor)s, and may produce improved ovarian stimulation. Metformin is used in PCOS cases in order to decrease plasma luteinizing hormone (LH), hyperinsulinemia, and ovarian androgen levels. Metformin increases the ovulatory rate, cervical scores and pregnancy rate. This review article focuses on the combined effect of metformin administration in PCOS patients. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
